Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision ...

Melt Pharmaceuticals has reported results from its Phase III trial of MELT-300 non-opioid sedation tablet for cataract ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

The trial considered dalzanemdor to treat cognitive impairment in Huntington’s disease patients. Credit: Kateryna Kon / Shutterstock. Sage Therapeutics announced yesterday (20 November) that its Phase ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The consortium aims to attract global pharma and medical device companies for clinical trial research investment in Israel.

The company’s ENS-002 is aimed at treating atopic dermatitis. Credit: © 2024 Concerto Biosciences, Inc. All rights reserved.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

Emmecell has published positive topline outcomes from a Phase I trial of EO2002, its nonsurgical cell therapy candidate for ...